Market research
SBPH Spring Bank Pharmaceuticals, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- 0.0%
- Beta
- 1.12
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8494311017
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- 0.0%
- Beta
- 1.12
About
About Spring Bank Pharmaceuticals, Inc
As of November 20, 2020, Spring Bank Pharmaceuticals, Inc. was acquired by F-star Therapeutics Limited, in a reverse merger transaction. Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SBPH discussion.
5 years, 4 months ago
Spring Bank Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 246.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Spring Bank Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 22.5% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.9% to $-4M since the same quarter in the previous year.
Based on the above factors, Spring Bank Pharmaceuticals, Inc gets an overall score of 4/5.